Latent Tuberculosis in Second Generation Immigrants From High Risk Countries Compare to Low-risk Young Israeli Adults

Better Identification of Latent Tuberculosis Infection Among Israeli Young Adults by Comparison Skin Tests and Interferon Gamma Releasing Assays (IGRA)

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02073669

Enrollment

115

Registered

2014-02-27

Start date

2014-03-31

Completion date

2018-11-30

Last updated

2019-01-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Latent Tuberculosis

Keywords

latent tuberculosis, tuberculin skin test, Interferon gamma release assay, immigration

Brief summary

The aim of study is to evaluate the prevalence of latent TB in second generation immigrants from countries with high incidence of tuberculosis (above 20 of 100,000) compare to the control native Israelis without a family member who was born in a country with high incidence of tuberculosis. Using study questionnaire IGRA and tuberculin skin test the investigators expect that the second generation immigrants group will have more positive IGRA test than the control native group.

Interventions

PROCEDUREAnswering the study Questionnaire and blood sampling for Interferon gamma release assay (IGRA)

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

DIAGNOSTIC

Masking

SINGLE (Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to 25 Years

Healthy volunteers

Yes

Inclusion criteria

* Age 18-25 * Men and women * Second generation immigrants from countries with high incidence of tuberculosis (above 20 of 100,000). * Native Israelis without a family member who was born in a country with high incidence of tuberculosis.

Exclusion criteria

* Prior contact with a tuberculosis patient * Working (more than a month) in high risk setting such as health care workers, working with immigrants from countries with high incidence of tuberculosis. * HIV infection and any immunodeficiency condition. * Recent live-virus vaccination * Acute infectious disease * Prior serious reaction to tuberculin skin test * Pregnancy

Design outcomes

Primary

Measure	Time frame
Interferon gamma release assay ( IGRA)	Up to 3 months after tuberculin skin test

Countries

Israel

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026